natgillin/translations-raw huggingface dataset:
DEKLARATION AV AKTIV SUBSTANS(ER) OCH ÖVRIGA SUBSTANSER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
DEKLARATION AV AKTIV(A) SUBSTANS OCH ÖVRIGA SUBSTANSER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
DEKLARATION AV AKTIV(A) SUBSTANS OCH ÖVRIGA SUBSTANSER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
DEKLARATION AV AKTIV(A) SUBSTANS(ER)
STATEMENT OF ACTIVE SUBSTANCE(S)
DEKLARATION AV AKTIV(A) SUBSTANS(ER) OCH ÖVRIGA SUBSTANSER
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Del 19
Del19
Delež atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, je bil pri prejemnicah 5 mg zoledronske kisline 1,3% (pri 51 od 3.862 bolnic) in pri prejemnicah placeba 0,6% (pri 22 od 3.852 bolnic).
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
Delež bolnikov s SRE (%)
Proportion of patients with SREs (%)
Delež bolnikov z bazalnoceličnim karcinomom proti ploščatoceličnim karcinomom kože (4:1) je primerljiv pričakovanemu deležu v splošni populaciji (glejte poglavje 4.4).
The ratio of patients with basal versus squamous cell skin cancers (4:1) is comparable with the ratio expected in the general population (see section 4.4).
Delež bolnikov z oceno PGA čisto (0) ali minimalno (1) in delež bolnikov, ki so dosegli PASI 75 je v prvem obisku po začetku zdravljenja (4. teden) pokazal razliko med skupino, ki je prejemala ustekinumab in skupino, ki je prejemala placebo, največjo razliko pa v 12. tednu.
The proportion of patients with a PGA score of cleared (0) or minimal (1) and the proportion achieving PASI 75 showed separation between the ustekinumab treated group and placebo at the first post-baseline visit at week 4, reaching a maximum by week 12.
Delež bolnikov, ki so dosegli klinično pomembno, ≥ 0,3 izboljšanje izhodiščne ocene HAQ-DI, je bil značilno večji v skupini, ki je prejemala ustekinumab v primerjavi s placebom.
The proportion of patients achieving a clinically meaningful ≥ 0.3 improvement in HAQ-DI score from baseline was also significantly greater in the ustekinumab groups when compared with placebo.
Delež odziva pri teh bolnikih je bil okrog 52%.
The response rate in these patients was about 52%.
Deleža odraslih bolnikov, pri katerih je prišlo do nastanka proti-pneumokoknih in proti-tetanusnih protiteles, sta bila v skupini, ki je prejemala zdravilo STELARA in kontrolni skupini, podobna.
Similar proportions of adult patients developed protective levels of anti-pneumococcal and anti-tetanus antibodies and antibody titers were similar among STELARA-treated and control patients.
Delovanje
Operation
Delpharm Lille S.A.S. Z.I. de Roubaix Est Rue de Toufflers 59390 Lys-Lez-Lannoy Франция
Delpharm Lille S.A.S. Z.I. de Roubaix Est Rue de Toufflers 59390 Lys-Lez-Lannoy France
Deltyba 50 mg филмирани таблетки деламанид (delamanid)
Deltyba 50 mg film-coated tablets delamanid
Deltyba 50 mg филмирани таблетки са кръгли и жълти.
Deltyba 50 mg film-coated tablets are round, and yellow.
Deltyba деламанид
Deltyba delamanid
Deltyba е антитуберкулозно лекарство, което съдържа активното вещество деламанид.
Deltyba is a tuberculosis medicine that contains the active substance delamanid.
Deltyba е разрешен за употреба по т.нар. схема „разрешаване под условие“.
Deltyba has been given ‘conditional approval’.
Deltyba не е подходящ за деца под 18 години.
Deltyba is not suitable for children under age 18.
Deltyba не се препоръчва при пациенти с чернодробно увреждане в умерена до тежка степен (вж. точки 4.2 и 5.2).
Deltyba is not recommended in patients with moderate to severe hepatic impairment (see sections 4.2 and 5.2).
Deltyba не трябва да се използва при пациенти, които имат ниски нива на албумин (белтък в кръвта).
Deltyba must not be used in patients who have low levels of albumin (a blood protein).
Deltyba се доставя в опаковки от 40 или 48 филмирани таблетки в блистери от алуминий/алуминий или в бутилки от тъмно стъкло с 50 или 300 таблетки.
Deltyba is supplied in packs of 40 or 48 film-coated tablets in aluminium/aluminium blisters, or in amber glass bottles of 50 or 300 tablets.
Deltyba се използва при възрастни пациенти с белодробна туберкулоза с множествена лекарствена резистентност (резистентна поне към изониазид и рифампицин, две стандартни антитуберкулозни лекарства).
Deltyba is used in adults with tuberculosis that is affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, two standard anti-tuberculosis medicines).
Deltyba се отпуска по лекарско предписание и лечението трябва да се започва и проследява от лекар с опит в лечението на белодробна туберкулоза с множествена лекарствена резистентност.
Deltyba can only be obtained with a prescription and treatment should be started and monitored by a doctor who is experienced in the treatment of multi-drug resistant tuberculosis.
Deltyba се прилага в рамките на 6 месеца заедно с други стандартни лекарства.
Deltyba is given for 6 months together with other standard medicines.
Deltyba съдържа активното вещество деламанид, антибиотик за лечение на туберкулоза на белия дроб, причинена от бактерии, които не се унищожават от най-често използваните антибиотици за лечение на туберкулоза.
Deltyba contains the active substance delamanid, an antibiotic for the treatment of tuberculosis in the lung caused by bacteria that are not killed by the most commonly used antibiotics to treat tuberculosis.
delší spánek než normálně (hypersomnie)
leeping more than normal (hypersomnia)
DEMO Ανώνυμος Βιομηχανική και Εμπορική
DEMO Ανώνυμος Βιομηχανική και Εμπορική Εταιρεία
Demografické a výchozí charakteristiky byly podobné u skupin atazanaviru s kobicistatem i atazanaviru s ritonavirem.
The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups.
Den absoluta biotillgängligheten av emtricitabin från Emtriva 200 mg hårda kapslar beräknades till 93 % och den absoluta biotillgängligheten från Emtriva 10 mg/ml oral lösning beräknades till 75 %.
The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/ml oral solution was estimated to be 75%.
Den aktiva substansen efter administrering av Zinforo är ceftarolin.
The active moiety after Zinforo administration is ceftaroline.
Den aktiva substansen är emtricitabin.
The active substance is emtricitabine.
Den anbefalede dosis torasemid er 0,1 til 0,6 mg pr. kg legemsvægt én gang dagligt.
The recommended dose of torasemide is 0.1 to 0.6 mg per kg bodyweight, once daily.
Den antiemetiska effekten kvarstår i minst 12 timmar, och tabletterna kan därför gärna ges kvällen före, vid tidig avresa.
The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel.
Den behandlingsfria periodens längd är också beroende av farmakokinetiken för de veterinärmedicinska läkemedel som använts tidigare.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
Den behandlingsfria periodens längd är också beroende av farmakokinetiken för de veterinärmedicinska läkemedel som använts tidigare.
The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.
Den behandlingsfria periodens längd är också beroende av farmakologiska egenskaper för de läkemedel som använts tidigare.
The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Den behandlingsfria periodens längd är också beroende av hur länge preparat som använts tidigare finns kvar i kroppen.
The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.
Den beredda flaskan ska användas omedelbart.
After reconstitution
Den beredda lösningen är blekt gul och partikelfri.
The reconstituted solution is pale yellow solution and free of particles.
Den färdiga lösningen ska administreras under 60 minuter för alla infusionsvolymer (50 ml, 100 ml eller 250 ml).
The resulting solution should be administered over 60 minutes for all infusion volumes (50 ml, 100 ml or 250 ml).
Den hämmar både Ambler klass A och klass C β-laktamaser och en del klass D-enzymer, inklusive betalaktamas med utvidgat spektrum (ESBL), KPC och OXA-48-karbapenemaser, och AmpC-enzymer.
It inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including extended-spectrum β-lactamases (ESBLs), KPC and OXA-48 carbapenemases, and AmpC enzymes.
Den indre emballages art og indhold
Nature and composition of immediate packaging
Den inhiberande spektrat av avibaktam inkluderar många av de enzymer som inaktiverar ceftazidim, inklusive Ambler klass A β-laktamaser och klass C β-laktamaser.
The inhibitory spectrum of avibactam includes many of the enzymes that inactivate ceftazidime, including Ambler class A β-lactamases and class C β-lactamases.
Den innehåller information som är viktig för dig.
Keep this leaflet.
Den innehåller också metakresol som konserveringsmedel.
It also contains metacresol (as preservative).
Den interindividuella variationen i kinetiken kan vara stor, upp till 70 CV% för AUC.
The inter-individual variation in kinetics may be large, up to 70 CV% for AUC.
Den kan döda många typer av bakterier.
It can kill many types of bacteria.
Den kemiska och fysikaliska stabiliteten vid användning har dokumenterats för upp till 24 timmars förvaring i 2-8 °C. När den utspädda produkten tagits ut ur kylskåpet till rumstemperatur måste den användas inom 6 timmar.
The chemical and physical in-use stability has been demonstrated for up to 24 hours at 2-8°C. Once removed from refrigeration to room temperature, the diluted product must be used within 6 hours.
Den klara lösningen är till färgen orange till mörkt orange.
The clear solution is orange to dark orange in colour.
Den normala dosen för vuxna är 600 mg var 12:e timme.
The usual dose for adults is 600 mg every 12 hours.
Den rekonstituerade lösningen måste spädas ytterligare för framställande av Zinforo infusionslösning.
The reconstituted solution must be further diluted to produce Zinforo solution for infusion.
Den resulterande lösningen ska administreras under 120 minuter.
The resulting solution should be administered over 120 minutes.
Den slutgiltiga studie rapporten ska
avibactam to meropenem.
Den systemiska exponeringen för emtricitabin (medelvärde ± standardavvikelsen) ökade från 11,8±2,9 µg*timme/ml hos individer med normal njurfunktion till 19,9±1,1, 25,0±5,7 respektive 34,0±2,1 µg*timme/ml, hos patienter med lätt, måttlig och svår njurfunktionsnedsättning.
The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 µg·h/ml in subjects with normal renal function to 19.9±1.1, 25.0±5.7 and 34.0±2.1 µg·h/ml, in patients with mild, moderate and severe renal impairment, respectively.
Den terminala halveringstiden (t½) för både ceftazidim och avibaktam är ungefär 2 timmar efter intravenös administrering.
The terminal half-life (t½) of both ceftazidime and avibactam is about 2 h after intravenous administration.
Den totala mängden
Total volume
Den totala stabiliteten vid användning, från beredning till administrering, får inte överskrida 36 timmar (24 timmar vid 2-8 °C plus 12 timmar i rumstemperatur).
The total in-use stability from reconstitution to administration should not exceed 36 hours (24 hours at 2-8°C plus 12 hours room temperature).
Den veterinärmedicinska produkten nyligen har godkänts för försäljning (juni 2011).
Recent marketing of the veterinary medicinal product (June 2011)
Dendreon UK Limited 41 Chalton Street London, NW1 1JD Обединено кралство
Dendreon UK Limited 41 Chalton Street London, NW1 1JD United Kingdom
Dendreon UK Limited 41 Chalton Street London, NW1 1JD Обединено кралство Тел.: +4420 7554 2222
Dendreon UK Limited 41 Chalton Street London, NW1 1JD United Kingdom
dendreonuk@dendreon.com
Fax: (0)20 7554 2201 dendreonuk@dendreon.com
Denmark/Danmark Cardiome UK Limited Tlf: +45 8082 6022
Denmark/ Danmark Cardiome UK Limited Tlf: +45 8082 6022
Denna aktiva substans är ett antiretroviralt läkemedel som används för att behandla hiv-infektion.
This active substance is an antiretroviral medicine which is used to treat HIV infection.
Denna bipacksedel ändrades senast .
This leaflet was last revised in .
Denna dos är hälften så stor som den dos som är godkänd för spädbarn från 4 månaders ålder (6 mg/kg).
This dose is half of that approved for infants aged 4 months and over (6 mg/kg).
Denna hiv-1-mutation sågs in vitro och hos hiv-1-infekterade patienter.
This HIV-1 mutation was observed in vitro and in HIV-1 infected patients.
Denna indikation baseras på studier av tidigare obehandlade patienter och tidigare behandlade patienter med stabil virologisk kontroll.
This indication is based on studies in treatment-naïve patients and treatment-experienced patients with stable virological control.
Denna produkt är endast för hästar som väger mellan 500 och 600 kg.
This product is only for use in horses weighing between 500 and 600 kg.
Denní dávku alli si můžete ponechat v modrém přenosném pouzdru (shuttle), které je součástí tohoto balení.
You can keep your daily dose of alli in the blue carry case (shuttle) included in this pack.
denně (atazanavir 400 mg jednou
(atazanavir 400 mg once daily)
denně, souběžné podání)
imultaneous administration)
DepoCyte 50 mg инжекционна суспензия
DepoCyte 50 mg suspension for injection
DepoCyte 50 mg инжекционна суспензия Цитарабин
DepoCyte 50 mg suspension for injection Cytarabine
DepoCyte e депо инжекция (вид инжекция, при която лекарството се приготвя по такъв начин, че да се абсорбира от тялото много бавно).
DepoCyte is a ‘depot’ injection (a type of injection where the medicine is prepared so that it is absorbed by the body very slowly).
DepoCyte е инжекционна суспензия, съдържаща 50 mg от активното вещество цитарабин (cytarabine).
DepoCyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
DepoCyte не бива да се прилага на бременни жени, тъй като може да увреди нероденото дете.
DepoCyte should not be given to pregnant women as it may harm an unborn child.
DepoCyte не бива да се прилага по никакъв друг начин.
DepoCyte must not be administered by any other way.
DepoCyte не трябва да се прилага по никакъв друг начин.
DepoCyte must not be administered by any other route of administration.
DepoCyte трябва да се използва във вида, в който се предлага; не трябва да се разрежда (вж. точка 6.2).
DepoCyte must be used as supplied; it must not be diluted (see section 6.2).
DepoCyte трябва да се използва възможно най-скоро след първоначалното разпечатване и обикновено трябва да се употреби в рамките на 4 часа (при съхранение при температура 18- 22ºC).
DepoCyte should be used as soon as possible after first opening, and should normally be used within 4 hours (stored at 18-22ºC).
Deprese
Depression
deprese, úzkost a poruchy spánku
depression, anxiety, sleep disorder
depresija
Depression
depresija,
Depression
Der blev demonstreret dosisproportionalitet for Cmax og AUCinf fra 0,2 til 1,6 mg/kg.
Dose proportionality for Cmax and AUCinf was demonstrated between 0.2 and 1.6 mg/kg.
Der bør udvises forsigtighed, når torasemid administreres sammen med andre lægemidler, der i høj grad er bundet til plasmaproteiner.
Care should be exercised when administering torasemide with other highly plasma protein bound drugs.
Der foreligger ingen oplysninger om sikkerhed og virkning ved brug af vaccinen sammen med andre lægemidler til dyr.
Overdose (symptoms, emergency procedures, antidotes):
Der kan observeres mave-tarm-problemer, som omfatter emese, nedsat eller ingen afføring og i sjældne tilfælde blød afføring.
Gastrointestinal signs which include emesis, reduced or absent faeces and, in rare cases, soft faeces may be observed.
dermalne okužb (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli and Proteus mirabilis
dermalne okužbe (okužbe mehkega tkiva – rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli, Proteus spp. in Pasteurella spp.
Dermal infections (soft tissue infections – wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp, E. coli, Proteus spp. and Pasteurella spp.
dermalne okužbe (okužbe mehkega tkiva – rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli, Proteus spp. in Pasteurella spp.
Dermal infections (soft tissue infections – wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Proteus spp. and Pasteurella spp.
dermalne okužbe (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible pathogens such as staphylococci, E. coli and Proteus mirabilis
dermalne okužbe (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp, E. coli and Proteus mirabilis.
dermalne okužbe (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi mikroorganizmi, kot so Staphylococcus spp., E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli and Proteus mirabilis.
Dermalne okužbe (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi sevi stafilokokov, E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, E. coli, and Proteus mirabilis.
Dermalne okužbe (pioderma – površinska in globoka, rane, abscesi), ki jih povzročajo občutljivi sevi, kot so stafilokoki, E. coli in Proteus mirabilis
Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains such as Staphylococci, E. coli, Proteus mirabilis.
Derudover kan der forekomme forhøjet rektal temperatur på op til 2,5C på vaccinationsdagen.
Furthermore, an increase in rectal temperature up to 2.5 °C may occur on the day of vaccination.
Descovy 200 mg/10 mg [Само върху вторичната опаковка]
Descovy 200 mg/10 mg [Outer packaging only]
Descovy 200 mg/10 mg филмирани таблетки
Descovy 200 mg/10 mg film-coated tablets
Descovy 200 mg/10 mg филмирани таблетки емтрицитабин/тенофовир алафенамид
Descovy 200 mg/10 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy 200 mg/25 mg [Само върху вторичната опаковка]
Descovy 200 mg/25 mg [Outer packaging only]
Descovy 200 mg/25 mg филмирани таблетки
Descovy 200 mg/25 mg film-coated tablets
Descovy 200 mg/25 mg филмирани таблетки емтрицитабин/тенофовир алафенамид
Descovy 200 mg/25 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy не е проучван при пациенти с тежко чернодробно увреждане (Child-Pugh клас C); затова Descovy не се препоръчва за употреба при пациенти с тежко чернодробно увреждане (вж. точки 4.4 и 5.2).
Descovy has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, Descovy is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Descovy не трябва да се прилага едновременно с лекарствени продукти, съдържащи тенофовир дизопроксил (като фумарат), емтрицитабин, ламивудин или адефовир дипивоксил.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), emtricitabine, lamivudine or adefovir dipivoxil.
Descovy не трябва да се прилага едновременно с лекарствени продукти, съдържащи тенофовир дизопроксил (като фумарат), ламивудин или адефовир дипивоксил, използвани за лечение на инфекция с HBV.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Descovy трябва да се използва по време на бременност, само ако потенциалната полза оправдава потенциалния риск за плода.
Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Descovy трябва да се прекрати при пациенти с изчислен CrCl, който спада под 30 ml/min по време на лечение (вж. точки 5.1 и 5.2).
Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Descovy трябва да се прилага, както е посочено в Таблица 1.
Descovy should be administered as shown in Table 1.
Descovy, в комбинация с други лекарства, е за лечение на инфекция с човешки имунодефицитен вирус тип 1 (Human Immunodeficiency Virus, HIV-1) при възрастни и юноши на и над 12 години, които тежат най-малко 35 kg.
Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Desfuroylceftiofur е най-важният активен метаболит.
Desfuroylceftiofur is the principal active metabolite.
Desitin Pharma AB Havnegade 55, st. tv.
Desitin Pharma AB Krokslätts Torg 5
Desitin Pharma AS Niels Leuchs vei 99 1359 Eiksmarka Норвегия
Desitin Pharma AS Niels Leuchs vei 99 1359 Eiksmarka Norway
Desloratadine Actavis 5 mg филмирани таблетки
Desloratadine Actavis 5 mg film-coated tablets
Desloratadine Actavis 5 mg филмирани таблетки деслоратадин
Desloratadine Actavis 5 mg film-coated tablets desloratadine
Desloratadine Actavis 5 mg филмирани таблетки деслоратадин
Desloratadine Actavis 5 mg tablets desloratadine
Desloratadine Actavis 5 mg филмирани таблетки са опаковани в: Блистери: 7, 10, 14, 20, 21, 30, 50, 90 или 100 таблетки.
Desloratadine Actavis 5 mg film-coated tablets are packed in: Blister packs: 7, 10, 14, 20, 21, 30, 50, 90 or 100 tablets.
Desloratadine Actavis е показан при възрастни и юноши на 12 и повече години за облекчаване на симптомите на:
Desloratadine Actavis is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Desloratadine Actavis е „генерично лекарство“.
Desloratadine Actavis is a ‘generic medicine’.
Desloratadine Actavis облекчава симптомите на алергичния ринит (възпаление на носните пътища, причинено от алергия, като например сенна хрема или алергия към домашен прах) при възрастни и юноши на 12 и повече години.
Desloratadine Actavis relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Desloratadine Actavis съдържа деслоратадин, който е антихистамин.
Desloratadine Actavis contains desloratadine which is an antihistamine.
Desloratadine ratiopharm 5 mg филмирани таблетки
Desloratadine ratiopharm 5 mg film-coated tablets
Desloratadine ratiopharm 5 mg филмирани таблетки Деслоратадин
Desloratadine ratiopharm 5 mg film-coated tablets Desloratadine
Desloratadine ratiopharm 5 mg филмирани таблетки е показан при възрастни и юноши на 12 и повече години за облекчаване на симптоми на:
Desloratadine ratiopharm 5 mg film-coated tablets is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Desloratadine ratiopharm е „генерично лекарство“.
Desloratadine ratiopharm is a ‘generic medicine’.